These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1916750)

  • 1. Uterine stromal neoplasms: a clinicopathologic and DNA flow cytometric correlation.
    el-Naggar AK; Abdul-Karim FW; Silva EG; McLemore D; Garnsey L
    Hum Pathol; 1991 Sep; 22(9):897-903. PubMed ID: 1916750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators.
    Malmström H; Schmidt H; Persson PG; Carstensen J; Nordenskjöld B; Simonsen E
    Gynecol Oncol; 1992 Feb; 44(2):172-7. PubMed ID: 1544595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
    Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
    Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoplasms of endometrial stroma: histopathologic and flow cytometric analysis with clinical correlation.
    August CZ; Bauer KD; Lurain J; Murad T
    Hum Pathol; 1989 Mar; 20(3):232-7. PubMed ID: 2722173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary sarcomas of the kidney. A clinicopathologic and DNA flow cytometric study of 17 cases.
    Grignon DJ; Ayala AG; Ro JY; el-Naggar A; Papadopoulos NJ
    Cancer; 1990 Apr; 65(7):1611-8. PubMed ID: 2155701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas.
    Wolfson AH; Wolfson DJ; Sittler SY; Breton L; Markoe AM; Schwade JG; Houdek PV; Averette HE; Sevin BU; Penalver M
    Gynecol Oncol; 1994 Jan; 52(1):56-62. PubMed ID: 8307502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcomas. French Federation of Cancer Centers (FNCLCC) Sarcoma Group.
    Collin F; Chassevent A; Bonichon F; Bertrand G; Terrier P; Coindra JM
    Cancer; 1997 Jun; 79(12):2371-9. PubMed ID: 9191525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric analysis of human uterine sarcomas and cell lines.
    Nelson KG; Haskill JS; Sloan S; Siegfried JM; Siegal GP; Walton L; Kaufman DG
    Cancer Res; 1987 Jun; 47(11):2814-20. PubMed ID: 3567904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.
    D'Angelo E; Spagnoli LG; Prat J
    Hum Pathol; 2009 Nov; 40(11):1571-85. PubMed ID: 19540555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric analysis of endometrial stromal sarcoma.
    Hitchcock CL; Norris HJ
    Am J Clin Pathol; 1992 Feb; 97(2):267-71. PubMed ID: 1546695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DNA content and cell cycle phase analysis in uterine sarcomas and its clinical significance].
    Tan X; Chen G
    Zhonghua Fu Chan Ke Za Zhi; 1999 Sep; 34(9):551-4. PubMed ID: 11360642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uterine sarcomas.
    Mbatani N; Olawaiye AB; Prat J
    Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():51-58. PubMed ID: 30306577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometric analysis of uterine sarcomas.
    Lennart K; Lennart B; Ulf S; Bernard T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):339-42. PubMed ID: 7835771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric DNA analysis of stage I endometrial carcinoma.
    Britton LC; Wilson TO; Gaffey TA; Lieber MM; Wieand HS; Podratz KC
    Gynecol Oncol; 1989 Sep; 34(3):317-22. PubMed ID: 2767522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrioid stromal sarcomas of the ovary. A clinicopathologic analysis of 23 cases.
    Young RH; Prat J; Scully RE
    Cancer; 1984 Mar; 53(5):1143-55. PubMed ID: 6198065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-grade stromal sarcoma: DNA flow cytometric analysis and estrogen progesterone receptor data.
    Dunton CJ; Kelsten ML; Brooks SE; Viglione MJ; Carlson JA; Mikuta JJ
    Gynecol Oncol; 1990 May; 37(2):268-75. PubMed ID: 2344973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial stromal sarcoma of uterus.
    Xue WC; Cheung AN
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):719-32. PubMed ID: 21820965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
    Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
    Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.